Rhythm Pharmaceuticals Inc (RYTM) Stock AnalysisRYTMRhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Rhythm Pharmaceuticals is currently a hold. The stock is priced at $86.17, significantly below analyst price targets, with the highest target at $159, suggesting substantial upside potential. However, the stock's RSI is at 25.888, indicating it is oversold, and the forward P/E ratio is extremely high at 526.32, which raises concerns about future earnings expectations. The recent insider selling trend, which increased by 288.14%, poses a risk to the stock's performance.

4 analysts cover RYTM: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 140.62.